Repare Therapeutics Inc. (RPTX)
NASDAQ: RPTX · Real-Time Price · USD
2.590
0.00 (0.00%)
Jan 22, 2026, 4:00 PM EST - Market closed
Repare Therapeutics Revenue
Repare Therapeutics had revenue of $11.62M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $11.87M, down -82.16% year-over-year. In the year 2024, Repare Therapeutics had annual revenue of $53.48M with 4.58% growth.
Revenue (ttm)
$11.87M
Revenue Growth
-82.16%
P/S Ratio
9.33
Revenue / Employee
$92,016
Employees
129
Market Cap
111.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 53.48M | 2.34M | 4.58% |
| Dec 31, 2023 | 51.13M | -80.70M | -61.21% |
| Dec 31, 2022 | 131.83M | 124.23M | 1,634.61% |
| Dec 31, 2021 | 7.60M | 7.47M | 5,529.63% |
| Dec 31, 2020 | 135.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 142.53M |
| MacroGenics | 127.63M |
| Agenus | 106.83M |
| Fortress Biotech | 62.30M |
| Seer, Inc. | 16.38M |
| Artiva Biotherapeutics | 251.00K |
| Inovio Pharmaceuticals | 182.34K |
RPTX News
- 6 days ago - Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc. - Business Wire
- 4 weeks ago - Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Business Wire
- 2 months ago - Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc. - Business Wire
- 2 months ago - Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewsWire
- 2 months ago - Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value - Benzinga
- 2 months ago - Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc. - Business Wire
- 3 months ago - Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Business Wire
- 6 months ago - Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - Business Wire